results suggest circulating B7-H3 is a valuable biomarker for non-small cell lung cancer (NSCLC) and an elevated level of circulating B7-H3 suggests a poor clinical character for NSCLC.

Upregulation of B7-H3 is associated with induction of immunosuppressive phenotype of dendritic cells in Non-small cell lung cancer microenvironment.

B7-H1 and B7-H3 are independent predictors of poorer survival in patients with non-small cell lung cancer.

Review/Meta-analysis: High B7-H3 expression was a significant indicator of lymph node metastasis and advanced TNM stage in non-small cell lung cancer.

B7-H3 hijacks SREBP-1/FASN signaling mediating abnormal lipid metabolism in lung cancer

B7-H3 protein is expressed in the majority of NSCLCs and is associated with smoking history. High levels of B7-H3 protein have a negative prognostic impact in lung carcinomas. Coexpression of B7-H3 with PD-L1 and B7-H4 is relatively low, suggesting a nonredundant biological role of these targets.

HIV-infected lung cancer patients had significantly higher tumor B7-H3 expression compared to HIV-uninfected controls, and importantly similar tumor PD-L1 expression, and PD-1and PD-L1 expression on TII.

Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.

The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.

B7-H3-Induced Signaling in lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor mutation Patterns.